Skip to main content
Erschienen in: World Journal of Urology 1/2009

01.02.2009 | Original Article

Upregulation of mRNA expression of MCP-1 by TGF-β1 in fibroblast cells from Peyronie’s disease

verfasst von: Carolin Szardening-Kirchner, Lutz Konrad, Ekkehard W. Hauck, Simone M. Haag, Oliver Eickelberg, Wolfgang Weidner

Erschienen in: World Journal of Urology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Peyronie’s disease (PD) is a localized connective tissue disorder of the penile tunica albuginea (TA) with a still obscure etiopathology. Recent studies from our laboratory have demonstrated differences in Smad3 and Smad4 gene expression of PD-fibroblasts and non-PD-fibroblasts after stimulation with recombinant TGF-β1 for 1 h. In the present study, we investigated gene expression of Smad2–Smad4 and Smad7 up to 6 h after stimulation with TGF-β1. As a positive control, MCP-1 gene expression was monitored.

Materials and methods

Cells with fibroblast characteristics were isolated from seven PD plaques and three TA controls. The cells were incubated with recombinant TGF-β1 for 2–6 h and expression of Smad2–Smad4, Smad7, and monocyte chemotactic protein-1 (MCP-1) was determined by quantitative real-time PCR.

Results

TGF-β1 treatment resulted in a statistically significant up-regulation of Smad7 and MCP-1 gene expression. Smad7 expression was increased after 2 h (P < 0.001) and was still high after 4 h (P < 0.05). No significant differences between fibroblasts from PD-patients compared to non-PD-patients were observed. MCP-1 peaked after 4 h (P < 0.001) and remained high up to 6 h (P < 0.01). PD-fibroblasts revealed a significantly increased MCP-1 gene expression compared to non-PD-fibroblasts (P = 0.013) after 2 h and remained significantly different also after 6 h (P = 0.038). Gene expression of Smad2–Smad4 did not change during stimulation with TGF-β1.

Conclusion

In conclusion, analysis of MCP-1 expression might be a useful marker for Peyronie’s disease.
Literatur
1.
Zurück zum Zitat Sasso F, Gulino G, Falabella R, D’Addessi A, Sacco E, D’Onofrio A, Bassi PF (2007) Peyronie’s disease: lights and shadows. Urol Int 78:1–9PubMedCrossRef Sasso F, Gulino G, Falabella R, D’Addessi A, Sacco E, D’Onofrio A, Bassi PF (2007) Peyronie’s disease: lights and shadows. Urol Int 78:1–9PubMedCrossRef
2.
Zurück zum Zitat Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, Engelmann U (2002) Epidemiology of Peyronie’s disease. Int J Impot Res 14:379–383PubMedCrossRef Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, Engelmann U (2002) Epidemiology of Peyronie’s disease. Int J Impot Res 14:379–383PubMedCrossRef
3.
Zurück zum Zitat Levine LA (2004) Peyronie’s Disease: what have we learned? J Sex Med 1:1–11CrossRef Levine LA (2004) Peyronie’s Disease: what have we learned? J Sex Med 1:1–11CrossRef
4.
Zurück zum Zitat Zargooshi J (2004) Trauma as the cause of Peyronie’s disease: penile fracture as a model of trauma. J Urol 172:186–188PubMedCrossRef Zargooshi J (2004) Trauma as the cause of Peyronie’s disease: penile fracture as a model of trauma. J Urol 172:186–188PubMedCrossRef
5.
Zurück zum Zitat Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF (1997) The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol 157:276–281PubMedCrossRef Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF (1997) The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol 157:276–281PubMedCrossRef
6.
Zurück zum Zitat El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF (1997) Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 158:1391–1394PubMedCrossRef El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF (1997) Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 158:1391–1394PubMedCrossRef
8.
Zurück zum Zitat Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18:816–827PubMedCrossRef Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18:816–827PubMedCrossRef
9.
Zurück zum Zitat Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGFβ activation. J Cell Sci 116(Pt2):217–224PubMedCrossRef Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGFβ activation. J Cell Sci 116(Pt2):217–224PubMedCrossRef
10.
Zurück zum Zitat Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577–584PubMedCrossRef Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577–584PubMedCrossRef
11.
Zurück zum Zitat El-Sakka AI, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF (1998) Histological and ultrastructural alterations in an animal model of Peyronie’s disease. Br J Urol 81:445–452PubMed El-Sakka AI, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF (1998) Histological and ultrastructural alterations in an animal model of Peyronie’s disease. Br J Urol 81:445–452PubMed
12.
Zurück zum Zitat Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF (2003) Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie’s disease. BJU Int 91:830–838PubMedCrossRef Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF (2003) Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie’s disease. BJU Int 91:830–838PubMedCrossRef
13.
Zurück zum Zitat El-Sakka AI, Selph CA, Yen TS, Dahiya R, Lue TF (1998) The effect of surgical trauma on rat tunica albuginea. J Urol 159:1700–1707PubMedCrossRef El-Sakka AI, Selph CA, Yen TS, Dahiya R, Lue TF (1998) The effect of surgical trauma on rat tunica albuginea. J Urol 159:1700–1707PubMedCrossRef
14.
Zurück zum Zitat Mulhall JP, Anderson MS, Lubrano T, Shankey TV (2004) Peyronie’s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 14:397–405CrossRef Mulhall JP, Anderson MS, Lubrano T, Shankey TV (2004) Peyronie’s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 14:397–405CrossRef
15.
Zurück zum Zitat Haag SM, Hauck EW, Szardening-Kirchner C, Diemer T, Cha ES, Weidner W, Eickelberg O (2007) Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie’s disease. Eur Urol 51:255–261PubMedCrossRef Haag SM, Hauck EW, Szardening-Kirchner C, Diemer T, Cha ES, Weidner W, Eickelberg O (2007) Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie’s disease. Eur Urol 51:255–261PubMedCrossRef
16.
Zurück zum Zitat Essed E, Schroeder FH (1985) New surgical treatment for Peyronie disease. Urology 25:582–587PubMedCrossRef Essed E, Schroeder FH (1985) New surgical treatment for Peyronie disease. Urology 25:582–587PubMedCrossRef
17.
Zurück zum Zitat Hauck EW, Bschleifer T, Diemer T, Manning M, Schroeder-Printzen I, Weidner W (2002) Long-term results of Essed-Schroeder plication by the use of non-absorbable Goretex sutures for correcting congenital penile curvature. Int J Impot Res 14:146–150PubMedCrossRef Hauck EW, Bschleifer T, Diemer T, Manning M, Schroeder-Printzen I, Weidner W (2002) Long-term results of Essed-Schroeder plication by the use of non-absorbable Goretex sutures for correcting congenital penile curvature. Int J Impot Res 14:146–150PubMedCrossRef
18.
Zurück zum Zitat Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):R34CrossRef Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):R34CrossRef
19.
Zurück zum Zitat Nakao A, Afrakhte M, Moren A, Nkayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P (1997) Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389:631–635PubMedCrossRef Nakao A, Afrakhte M, Moren A, Nkayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P (1997) Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389:631–635PubMedCrossRef
20.
Zurück zum Zitat Afrakhte M, Moren A, Jossan S, Itoh S, Sampath K, Westermark B, Heldin CH, Heldin NE, ten Dijke P (1998) Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun 249:505–511PubMedCrossRef Afrakhte M, Moren A, Jossan S, Itoh S, Sampath K, Westermark B, Heldin CH, Heldin NE, ten Dijke P (1998) Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun 249:505–511PubMedCrossRef
21.
Zurück zum Zitat Denissova NG, Liu F (2004) Repression of endogenous Smad7 by Ski. J Biol Chem 279:28143–28148PubMedCrossRef Denissova NG, Liu F (2004) Repression of endogenous Smad7 by Ski. J Biol Chem 279:28143–28148PubMedCrossRef
22.
Zurück zum Zitat Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685–700PubMedCrossRef Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685–700PubMedCrossRef
23.
Zurück zum Zitat Massague J, Wotton D (2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19:1745–1754PubMedCrossRef Massague J, Wotton D (2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19:1745–1754PubMedCrossRef
24.
25.
Zurück zum Zitat Bonniaud P, Kolb M, Galt T, Robertson J, Robbins C, Stampfli M, Lavery C, Margetts PJ, Roberts AB, Gauldie J (2004) Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J Immunol 173:2099–2108PubMed Bonniaud P, Kolb M, Galt T, Robertson J, Robbins C, Stampfli M, Lavery C, Margetts PJ, Roberts AB, Gauldie J (2004) Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J Immunol 173:2099–2108PubMed
26.
Zurück zum Zitat Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB (1999) Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1:260–266PubMedCrossRef Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB (1999) Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1:260–266PubMedCrossRef
27.
Zurück zum Zitat Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, Ten Dijke P, Gressner AM (2003) Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 125:178–191PubMedCrossRef Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, Ten Dijke P, Gressner AM (2003) Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 125:178–191PubMedCrossRef
28.
Zurück zum Zitat Saika S, Ikeda K, Yamanaka O, Miyamoto T, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Nakajima Y, Kao WW, Flanders KC, Roberts AB (2005) Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali. Am J Pathol 166:1405–1418PubMed Saika S, Ikeda K, Yamanaka O, Miyamoto T, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Nakajima Y, Kao WW, Flanders KC, Roberts AB (2005) Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali. Am J Pathol 166:1405–1418PubMed
29.
Zurück zum Zitat Yoshimura H, Nakahama K, Safronova O, Tanaka N, Muneta T, Morita I (2006) Transforming growth actor-beta stimulates IL-1beta-induced monocyte chemoattractant protein-1 expression in human synovial cells via the ERK/AP-1 pathway. Inflamm Res 55:543–549PubMedCrossRef Yoshimura H, Nakahama K, Safronova O, Tanaka N, Muneta T, Morita I (2006) Transforming growth actor-beta stimulates IL-1beta-induced monocyte chemoattractant protein-1 expression in human synovial cells via the ERK/AP-1 pathway. Inflamm Res 55:543–549PubMedCrossRef
30.
Zurück zum Zitat Lin CS, Lin G, Wang Z, Maddah SA, Lue TF (2002) Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie’s disease. Biochem Biophys Res Commun 295:1014–1019PubMedCrossRef Lin CS, Lin G, Wang Z, Maddah SA, Lue TF (2002) Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie’s disease. Biochem Biophys Res Commun 295:1014–1019PubMedCrossRef
31.
Zurück zum Zitat Lin GT, Wang Z, Liu BC, Lue TF, Lin CS (2005) Identification of potential biomarkers of Peyronie’s disease. Asian J Androl 7:237–243PubMedCrossRef Lin GT, Wang Z, Liu BC, Lue TF, Lin CS (2005) Identification of potential biomarkers of Peyronie’s disease. Asian J Androl 7:237–243PubMedCrossRef
32.
Zurück zum Zitat Ma J, Wang Q, Fei T, Jackie Han JD, Chen YG (2007) MCP-1 mediates TGF-β-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 109:987–994PubMedCrossRef Ma J, Wang Q, Fei T, Jackie Han JD, Chen YG (2007) MCP-1 mediates TGF-β-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 109:987–994PubMedCrossRef
33.
Zurück zum Zitat Wang Z, Lin G, Lue TF, Lin CS (2003) Wogonin suppresses cellular proliferation and expression of monocyte chemoattractant protein 1 in Peyronie’s plaque-derived cells. BJU Int 92:753–757PubMedCrossRef Wang Z, Lin G, Lue TF, Lin CS (2003) Wogonin suppresses cellular proliferation and expression of monocyte chemoattractant protein 1 in Peyronie’s plaque-derived cells. BJU Int 92:753–757PubMedCrossRef
Metadaten
Titel
Upregulation of mRNA expression of MCP-1 by TGF-β1 in fibroblast cells from Peyronie’s disease
verfasst von
Carolin Szardening-Kirchner
Lutz Konrad
Ekkehard W. Hauck
Simone M. Haag
Oliver Eickelberg
Wolfgang Weidner
Publikationsdatum
01.02.2009
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 1/2009
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-008-0320-x

Weitere Artikel der Ausgabe 1/2009

World Journal of Urology 1/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.